Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
2.
J Allergy Clin Immunol ; 143(6): 2120-2130, 2019 06.
Article in English | MEDLINE | ID: mdl-30578879

ABSTRACT

BACKGROUND: Biologic therapies can be highly effective for the treatment of severe psoriasis, but response for individual patients can vary according to drug. Predictive biomarkers to guide treatment selection could improve patient outcomes and treatment cost-effectiveness. OBJECTIVE: We sought to test whether HLA-C*06:02, the primary genetic susceptibility allele for psoriasis, predisposes patients to respond differently to the 2 most commonly prescribed biologics for psoriasis: adalimumab (anti-TNF-α) and ustekinumab (anti-IL-12/23). METHODS: This study uses a national psoriasis registry that includes longitudinal treatment and response observations and detailed clinical data. HLA alleles were imputed from genome-wide genotype data for 1326 patients for whom 90% reduction in Psoriasis Area and Severity Index score (PASI90) response status was observed after 3, 6, or 12 months of treatment. We developed regression models of PASI90 response, examining the interaction between HLA-C*06:02 and drug type (adalimumab or ustekinumab) while accounting for potentially confounding clinical variables. RESULTS: HLA-C*06:02-negative patients were significantly more likely to respond to adalimumab than ustekinumab at all time points (most strongly at 6 months: odds ratio [OR], 2.95; P = 5.85 × 10-7), and the difference was greater in HLA-C*06:02-negative patients with psoriatic arthritis (OR, 5.98; P = 6.89 × 10-5). Biologic-naive patients who were HLA-C*06:02 positive and psoriatic arthritis negative demonstrated significantly poorer response to adalimumab at 12 months (OR, 0.31; P = 3.42 × 10-4). Results from HLA-wide analyses were consistent with HLA-C*06:02 itself being the primary effect allele. We found no evidence for genetic interaction between HLA-C*06:02 and ERAP1. CONCLUSION: This large observational study suggests that reference to HLA-C*06:02 status could offer substantial clinical benefit when selecting treatments for severe psoriasis.


Subject(s)
Adalimumab/therapeutic use , Biological Therapy/methods , Biomarkers, Pharmacological , Genotype , HLA-C Antigens/genetics , Psoriasis/genetics , Ustekinumab/therapeutic use , Adult , Alleles , Female , Genetic Predisposition to Disease , Humans , Male , Middle Aged , Polymorphism, Genetic , Predictive Value of Tests , Prognosis , Psoriasis/diagnosis , Psoriasis/drug therapy , Severity of Illness Index , Treatment Outcome , Young Adult
3.
Sci Transl Med ; 6(223): 223ra22, 2014 Feb 12.
Article in English | MEDLINE | ID: mdl-24523322

ABSTRACT

Cytokines are critical checkpoints of inflammation. The treatment of human autoimmune disease has been revolutionized by targeting inflammatory cytokines as key drivers of disease pathogenesis. Despite this, there exist numerous pitfalls when translating preclinical data into the clinic. We developed an integrative biology approach combining human disease transcriptome data sets with clinically relevant in vivo models in an attempt to bridge this translational gap. We chose interleukin-22 (IL-22) as a model cytokine because of its potentially important proinflammatory role in epithelial tissues. Injection of IL-22 into normal human skin grafts produced marked inflammatory skin changes resembling human psoriasis. Injection of anti-IL-22 monoclonal antibody in a human xenotransplant model of psoriasis, developed specifically to test potential therapeutic candidates, efficiently blocked skin inflammation. Bioinformatic analysis integrating both the IL-22 and anti-IL-22 cytokine transcriptomes and mapping them onto a psoriasis disease gene coexpression network identified key cytokine-dependent hub genes. Using knockout mice and small-molecule blockade, we show that one of these hub genes, the so far unexplored serine/threonine kinase PIM1, is a critical checkpoint for human skin inflammation and potential future therapeutic target in psoriasis. Using in silico integration of human data sets and biological models, we were able to identify a new target in the treatment of psoriasis.


Subject(s)
Psoriasis/drug therapy , Psoriasis/metabolism , Animals , Antibodies, Monoclonal/therapeutic use , Disease Models, Animal , Humans , Interleukins/antagonists & inhibitors , Interleukins/toxicity , Mice , Mice, Knockout , Psoriasis/chemically induced , Interleukin-22
4.
J Invest Dermatol ; 134(4): 984-991, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24352038

ABSTRACT

Innate lymphoid cells (ILCs) are increasingly appreciated as key regulators of tissue immunity. However, their role in human tissue homeostasis and disease remains to be fully elucidated. Here we characterize the ILCs in human skin from healthy individuals and from the inflammatory skin disease psoriasis. We show that a substantial proportion of IL-17A and IL-22 producing cells in the skin and blood of normal individuals and psoriasis patients are CD3-negative innate lymphocytes. Deep immunophenotyping of human ILC subsets showed a statistically significant increase in the frequency of circulating NKp44+ ILC3 in the blood of psoriasis patients compared with healthy individuals or atopic dermatitis patients. More than 50% of circulating NKp44+ ILC3 expressed cutaneous lymphocyte-associated antigen, indicating their potential for skin homing. Analysis of skin tissue revealed a significantly increased frequency of total ILCs in the skin compared with blood. Moreover, the frequency of NKp44+ ILC3 was significantly increased in non-lesional psoriatic skin compared with normal skin. A detailed time course of a psoriasis patient treated with anti-tumor necrosis factor showed a close association between therapeutic response, decrease in inflammatory skin lesions, and decrease of circulating NKp44+ ILC3. Overall, data from this initial observational study suggest a potential role for NKp44+ ILC3 in psoriasis pathogenesis.


Subject(s)
Dermatitis, Atopic/immunology , Immunity, Innate , Lymphocytes/immunology , Natural Cytotoxicity Triggering Receptor 2/metabolism , Psoriasis/immunology , Skin/immunology , Adult , Biomarkers/metabolism , CD3 Complex/metabolism , Dermatitis, Atopic/blood , Dermatitis, Atopic/metabolism , Female , Flow Cytometry , Gene Expression Regulation , Homeostasis , Humans , Immunophenotyping , Interleukin-17/immunology , Interleukins/immunology , Leukocytes, Mononuclear/cytology , Male , Middle Aged , Psoriasis/blood , Psoriasis/metabolism , Skin/metabolism , Skin/pathology , Interleukin-22
5.
Annu Rev Pathol ; 7: 385-422, 2012.
Article in English | MEDLINE | ID: mdl-22054142

ABSTRACT

Psoriasis is a common relapsing and remitting immune-mediated inflammatory disease that affects the skin and joints. This review focuses on current immunogenetic concepts, key cellular players, and axes of cytokines that are thought to contribute to disease pathogenesis. We highlight potential therapeutic targets and give an overview of the currently used immune-targeted therapies.


Subject(s)
Psoriasis , Cytokines/antagonists & inhibitors , Cytokines/immunology , Humans , Psoriasis/drug therapy , Psoriasis/genetics , Psoriasis/immunology , Psoriasis/pathology , Skin/pathology
6.
Immunity ; 35(6): 857-69, 2011 Dec 23.
Article in English | MEDLINE | ID: mdl-22195743

ABSTRACT

The skin provides the first line defense of the human body against injury and infection. By integrating recent findings in cutaneous immunology with fundamental concepts of skin biology, we portray the skin as a multitasking organ ensuring body homeostasis. Crosstalk between the skin and its microbial environment is also highlighted as influencing the response to injury, infection, and autoimmunity. The importance of the skin immune network is emphasized by the identification of several skin-resident cell subsets, each with its unique functions. Lessons learned from targeted therapy in inflammatory skin conditions, such as psoriasis, provide further insights into skin immune function. Finally, we look at the skin as an interacting network of immune signaling pathways exemplified by the development of a disease interactome for psoriasis.


Subject(s)
Skin/immunology , Animals , Humans , Skin/metabolism , Skin Diseases/immunology
7.
J Immunol ; 187(5): 2783-93, 2011 Sep 01.
Article in English | MEDLINE | ID: mdl-21813772

ABSTRACT

γδ T cells mediate rapid tissue responses in murine skin and participate in cutaneous immune regulation including protection against cancer. The role of human γδ cells in cutaneous homeostasis and pathology is characterized poorly. In this study, we show in vivo evidence that human blood contains a distinct subset of proinflammatory cutaneous lymphocyte Ag and CCR6-positive Vγ9Vδ2 T cells, which is rapidly recruited into perturbed human skin. Vγ9Vδ2 T cells produced an array of proinflammatory mediators including IL-17A and activated keratinocytes in a TNF-α- and IFN-γ-dependent manner. Examination of the common inflammatory skin disease psoriasis revealed a striking reduction of circulating Vγ9Vδ2 T cells in psoriasis patients compared with healthy controls and atopic dermatitis patients. Decreased numbers of circulating Vγ9Vδ2 T cells normalized after successful treatment with psoriasis-targeted therapy. Taken together with the increased presence of Vγ9Vδ2 T cells in psoriatic skin, these data indicate redistribution of Vγ9Vδ2 T cells from the blood to the skin compartment in psoriasis. In summary, we report a novel human proinflammatory γδ T cell involved in skin immune surveillance with immediate response characteristics and with potential clinical relevance in inflammatory skin disease.


Subject(s)
Psoriasis/immunology , Psoriasis/pathology , Receptors, Antigen, T-Cell, gamma-delta/immunology , Skin/immunology , Skin/pathology , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/pathology , Adult , Antigens, Differentiation, T-Lymphocyte/biosynthesis , Antigens, Differentiation, T-Lymphocyte/immunology , Cell Separation , Chemokines/analysis , Chemokines/biosynthesis , Chemotaxis, Leukocyte/immunology , Female , Flow Cytometry , Fluorescent Antibody Technique , Humans , Immunohistochemistry , Inflammation/immunology , Inflammation/metabolism , Inflammation/pathology , Male , Middle Aged , Psoriasis/metabolism , Receptors, CCR6/biosynthesis , Receptors, CCR6/immunology , Reverse Transcriptase Polymerase Chain Reaction , T-Lymphocyte Subsets/metabolism
8.
Pediatr Dermatol ; 23(1): 24-6, 2006.
Article in English | MEDLINE | ID: mdl-16445406

ABSTRACT

We describe an infant girl who was referred to us because of a lumbosacral swelling. She was also found to have two nonblanching, erythematous macules, one at the cervical level and one at the lumbosacral level. Occult spinal dysraphism was demonstrated by magnetic resonance imaging.


Subject(s)
Erythema/diagnosis , Magnetic Resonance Imaging , Spinal Dysraphism/diagnosis , Diagnosis, Differential , Female , Humans , Infant , Lumbosacral Region , Myelography/methods , Risk Assessment , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...